Clinical Trials Browser

Phase 2 × Withdrawn × ruxolitinib × Clear all

NCT04016116 2020-05-27

Dual PD-1 and JAK2 Inhibition in Hematological Malignancies

Phase 2 Withdrawn

Other hematologic neoplasm

Neoplasms, Hematologic Neoplasms